{{short description|Potential vaccine or vaccines against COVID-19}}
[[File:COVID-19 vaccine map.svg|thumb|right|400px|
ဗီုတိ မထ္ၜး ဍုင်မပဒတန် ဝက်သိန်ဂမၠိုင်
{{legend|Green|Approved for general use, mass vaccination underway}}
{{legend|SpringGreen|[[:w:Emergency Use Authorization|{{abbr|EUA|emergency use authorization}}]] granted, mass vaccination underway}}
{{legend|DarkOrange|{{abbr|EUA|emergency use authorization}} granted, limited vaccination}}
{{legend|Blue|Approved for general use, mass vaccination planned}}
{{legend|DodgerBlue|{{abbr|EUA|emergency use authorization}} granted, mass vaccination planned}}
{{legend|Gold|{{abbr|EUA|emergency use authorization}} pending}}]]

'''ဝက်သိန် ကဝ်ဝိဒ်-၁၉'''  ({{Lang-en| '''COVID‑19 vaccine'''}}) ဂှ် ဒှ် ဝက်သိန် မပကဵု ညံင်[[ဒြဟတ်အိမ်မုန်]]မသ္ဂောအ်တီ သွက်ဂွံဒစဵုဒစး ယဲကဝ်ဝိဒ်-၁၉။ ကိုပ်ကၠာ ကပ်ယဲကဝ်ဝိဒ်-၁၉ ဟွံကတဵုဒှ်ဏီဂှ်ရ၊ တၠပညာတအ် ကၠောန်ပ္တိတ်လဝ် ဝက်သေန် သွက်ဂွံဗတိုက် ကဝ်ရဝ်နာဝဳရုသ် မပကဵု ညံင်ဂွံဒှ်ယဲသာ (SARS) ကေုာံ ယဲမာ (MERS)တုဲ တၠပညာတအ် တီကၠိုဟ်လဝ် ပရူလဒက်ပ္တန် ကေုာံ တၠုင်လအာ ကဝ်ရဝ်နာဝဳရုသ်တုဲ ကာလ ကဝ်ရဝ်နာဝဳရုသ်ဂကူတၞဟ် မပကဵု ညံင်ဂွံဒှ် ယဲကဝ်ဝိဒ်-၁၉ ကတဵုဒှ် ပ္ဍဲတမ်သၞာံ ၂၀၂၀ ဂှ် ညးတအ် ဂစာန်ကၠောန် ဝက်သိန်-ကဝ်ဝိဒ်-၁၉။ 

စိုပ်ၜိုတ် လဒေါဝ်ဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် လၟောဝ်ဝက်သိန် ၅၇ ဂှ် ဂစာန်ကၠောန် ပဒၟံင်သုတေသနဂဥုဲတုဲ ပၞောဝ်တအ်ဂှ် ၄၀ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ပထမ - ဒုတိယတုဲ ၁၇ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ဒုတိယ - တတိယ။ ပ္ဍဲကဆံင်ကာလစွမ်တတိယဂှ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင် ကၠောန်ကမၠောန် ၜိုတ် ၉၅% သွက်ဂွံစဵုဒၞာ ယဲကဝ်ဝိဒ်-၁၉။<ref>{{Cite web|last=Santiago|first=Jahleah|date=2020-12-19|title=A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines|url=https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines/|url-status=live|archive-url=|archive-date=|access-date=2020-12-24|website=STAT|language=en-US}}</ref> ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵု ပဒတန်တုဲ ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵုဟွံပဒတန်ရ။ သီုဖအိုတ် မဂွံဒုင်ပဒတန် နကဵု အေဂျေန်သဳ ထတ်ယုက်ဍုင်တအ်ဂှ် နွံ မသုန် မပ္တံကဵု တဝ်ဇြဳနာမေရန် (Tozinameran) မကၠောန်ပ္တိတ် နူကဵု ဖြိဇြေရ်-ဗဳသြတေက် (Pfizer–BioNTech)၊ ဗဳဗဳဗ်-ကောဝ် (BBIBP-CorV) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဖာမ် (Sinopharm)၊ ကဝ်ရဝ်နာဝက် (CoronaVac) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဝက် (Sinovac)၊ အာမ်အာနာ-၁၂၇၃ (mRNA-1273) မကၠောန်ပ္တိတ် နူကဵု မဝ်ဒေရ်နာ (Moderna) ကေုာံ ဂမ်-ကဝ်ဝိဒ်-ဝက် (Gam-COVID-Vac) မကၠောန်ပ္တိတ် နူကဵု  အေန်သတဳကျုတ်သုတေသနဂမလေယာ (Gamaleya Research Institute)။ 

ဖြိဇြေရ်၊ မဝ်ဒေရ်နာ ကေုာံ သြသတြဇြေနေက (AstraZeneca) တအ် ဟီုလဝ် ပ္ဍဲသၞာံ ၂၀၂၁ မ္ဂး ညးတအ် ကၠောန်ပ္တိတ် လၟိဟ် ၅.၃&nbsp;ဗဳလဳယာန် သွုင် မာန်တုဲ ကလိဂွံ မၞိဟ်ၜိုတ် ၃ ဗဳလဳယာန်မာန် (မၞိဟ်မွဲမ္ဂး ဒးထ္ပက် ၂ သွုင်/တၞိင် သွက်ဂွံစဵုဒၞာ ကဝ်ဝိဒ်-၁၉)၊ ပ္ဍဲဂိတုဒဳဇြေမ်ဗါဂှ် နူကဵု ဍုင်နာနာတအ် ဗကန်လဝ် နူကဵုဌာနပ္တိတ်ဝက်သိန်တအ် လၟိဟ် ၁၀ ဗဳလဳယာန်ပြင်င်<ref name="mullard">{{cite journal|first1=Asher | last1=Mullard |date=30 November 2020|title=How COVID vaccines are being divvied up around the world Canada leads the pack in terms of doses secured per capita|url=https://www.nature.com/articles/d41586-020-03370-6|journal=Nature|doi=10.1038/d41586-020-03370-6|pmid=33257891|access-date=11 December 2020|s2cid=227246811}}</ref> ကဝက်ပြင်င်ဂှ် ဍုင်ပိုန်ဒြပ်ဇၞော်မောဝ်တအ် ဗကန်လဝ်တုဲ ဟီုကဵုလၟိဟ်မၞိဟ်ဂၠးကဝ်မ္ဂး ဍုင်သေဋ္ဌဳတအ်ဂှ် လၟိဟ်မၞိဟ် နွံ ၁၄% ဓဝ်ရ။<ref name="So">{{cite journal|last=So|first=Anthony D|last2=Woo|first2=Joshua|date=December 2020|title=Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis|journal=BMJ|page=m4750|doi=10.1136/bmj.m4750|issn=1756-1833|name-list-style=vanc|doi-access=free}}</ref> ဍုင်ဗွဲမဂၠိုင်တအ်ဂှ် ဖျေဟ်လၟေင်ကမၠောန် ထပက်ဝက်သိန် နကဵု မၞိဟ်ဗယု၊ ယဲဇမၠိင် မဒှ်မၞိဟ်အန္တရာယ်ဇၞော် ကုယဲကဝ်ဝိဒ်-၁၉ ကေုာံ အစာဂဥုဲ အစာသဝ်ဂှ် ကဵုထ္ပက်ကၠာရ။<ref>{{Cite news|last=Beaumont|first=Peter|date=2020-11-18|title=Covid-19 vaccine: who are countries prioritising for first doses?|language=en-GB|work=The Guardian|url=https://www.theguardian.com/world/2020/nov/18/covid-19-vaccine-who-are-countries-prioritising-for-first-doses|access-date=2020-12-26|issn=0261-3077}}</ref>

==လၟေင်ကမၠောန် ကေုာံ ဓလိုက်တမ်ရိုဟ်==
ပ္ဍဲမွဲဒမြိပ်သၞာံ ၂၀၂၀ နူစ သၞာံမံက်၊ ယဲကပ်စကတဵုဒှ်ဂှ် ဌာနမကၠောန်ပ္တိတ်ဂဥုဲဂမၠိုင်၊ အလဵုအသဳဍုင် ကေုာံ ကမ္မဏဳမဆေင်ကဵုဇဳဝဗေဒ နူကဵု ရးနိဂီုနာနာ ပ္တိတ်အာရီု ဂစာန်ကၠောန်ကၠုင် သွက်ကလိဂွံ ဝက်သိန်ကဝ်ဝိဒ်-၁၉ အိုတ်ရ။<ref name="thanh2">{{cite journal|last1=Le|first1=Tung Thanh|last2=Cramer|first2=Jakob P.|last3=Chen|first3=Robert|last4=Mayhew|first4=Stephen|date=4 September 2020|title=Evolution of the COVID-19 vaccine development landscape|journal=Nature Reviews Drug Discovery|volume=19|issue=10|pages=667–68|doi=10.1038/d41573-020-00151-8|issn=1474-1776|pmid=32887942|doi-access=free|s2cid=221503034|name-list-style=vanc}}</ref> အတိုင် ဂကောံပံင်ကောံမခၞံဗဒှ်သွက်စဵုဒၞာကပ်ယဲ (Coalition for Epidemic Preparedness Innovations -CEPI) မဗမံက်ထ္ၜးလဝ်မ္ဂး ဂကောံမပါလုပ် ပ္ဍဲအရာမကၠောန်ပ္တိတ် ဝက်သိန်ဏအ်ဂှ် နူကဵု အမေရိသၟဝ်ကျာဂှ် ၜိုတ် ၄၀%၊ အာရှ ကဵု အဝ်သတြေလျာ ၃၀%၊ ဥရောပ ၂၆% တုဲ ပ္ဍဲအမေရိသၠုင်ကျာ ကဵု အာဖရိကဂှ် ပါလုပ်ညိညကီုရ။<ref name="thanh2" /><ref name="thanh" />

လၟောဝ်ဝက်သိန်မွဲမွဲ ဂွံကလိဂွံဇမၞးမာန်ဂှ် ဒးအိုတ်သြန် ဗွဲမဂၠိုင်ဂၠေင်ရ။ ဥပမာ ခရိတ်င္ၚုဟ်အိုတ် ပ္ဍဲ ကာလစွမ်မၞိဟ်အလန်ပထမဂှ်သၟးဂှ် ဒးအိုတ် သြန်ဒဝ်လာအမေရိကာန် အကြာ ၁၄ မဳလဳယာန်ကဵု  ၂၅ မဳလဳယာန်။<ref name="gouglas">{{cite journal|vauthors=Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA|date=December 2018|title=Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study|journal=Lancet Global Health|volume=6|issue=12|pages=e1386–96|doi=10.1016/S2214-109X(18)30346-2|pmc=7164811|pmid=30342925}}</ref><ref name="dimasi">{{cite journal|vauthors=DiMasi JA, Grabowski HG, Hansen RW|date=May 2016|title=Innovation in the pharmaceutical industry: New estimates of R&D costs|journal=Journal of Health Economics|volume=47|pages=20–33|doi=10.1016/j.jhealeco.2016.01.012|pmid=26928437|doi-access=free|hdl-access=free|hdl=10161/12742}}</ref> ယဝ်ဒးပတုပ် နကဵုဥပမာမ္ဂး အခိင်ကာလ ကပ်ယဲအဳဗဝ်လာဝဳရုသ် (Ebola virus) မကတဵုဒှ် အကြာ ၂၀၁၃-၁၆ ဂှ် လၟောဝ်ဝက်သိန် သီုဖအိုတ် ဂစာန်ကၠောန် ၃၇ ဂှ် ဆဝက်သိန်မွဲဟေင် ကလိဂွံအခေါင်လာင်ဇြေန် သွက်ဂွံစကာ နဒဒှ် ဝက်သိန်၊ ညးမပ္တိတ်ဂှ် ခရိတ်စမ် ကာလစွမ်ဒုတိယ-တတိယဂှ် ဒးစကာသြန် ဒဝ်လာအမေရိကာန် ၜိုတ် ၁ ဗဳလဳယာန်။<ref name="gouglas"/>

=== ဂကောံ ရးနိဂီုနာနာ ===

====Access to COVID-19 Tools (ACT) Accelerator ကေုာံ COVAX====

ပရေင်ပံင်ကောံ ဂကောံဂၠးကဝ်နာနာ မပ္တံကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် (WHO)၊ ဂကောံပံင်ကောံ သွက်ဂၠိုက်ဂၠာဲ အရာမဒစဵုဒစး ကပ်ယဲ(CEPI)၊ GAVI၊ Gates Foundation ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ပံင်ကောံတုဲ ဒက်ပ္တန်လဝ် အေသဳတဳ (ACT) မဂွံအဓိပ္ပါယ် ကလိဂွံ ကပေါတ်သွက်ယဲကဝ်ဝိဒ်-၁၉ တအ် ပံင်ကောံတုဲ ဂၠာဲသြန်ဗွဝ် သွက်ဂွံထံက်ပင် ကမၠောန်လ္ၚတ်သုတေသန၊ ပ္တိတ်ကပေါတ်စွမ်ယဲ၊ ဂဥုဲလွဳ ကေုာံ ကဵုလာင်ဇြေန်ဝက်သိန် မဒှ်ပရေင်ကမၠောန် နကဵုက္ဍိုပ်လိက် "ကဝ်ဝဇ် ပိလ္လာရ် (COVAX Pillar)"။<ref name="who-covax">{{Cite web|date=2020|title=What is the ACT Accelerator?|url=https://www.who.int/initiatives/act-accelerator/about|url-status=live|archive-url=https://web.archive.org/web/20200925122714/https://www.who.int/initiatives/act-accelerator/|archive-date=25 September 2020|access-date=2020-08-29|publisher=World Health Organization}}</ref><ref name="covax-gavi-09">{{cite web|date=2020-09-01|title=What is COVAX?|url=https://www.gavi.org/vaccineswork/covax-explained|access-date=11 December 2020|publisher=GAVI}}</ref> နကဵု ကဝ်ဝက်ပိလ္လာရ်ဂှ် စွံလဝ် တင်ရန်တၟအ် ညံင်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင်တုဲ လအိတ်သၞာံ ၂၀၂၁ မ္ဂး ညံင်ဂွံပ္တိတ် စဵုကဵု ၂ ဗဳလဳယာန်သွုင် သွက်ဂွံစဵုဒၞာ သၟာကမၠောန်ထတ်ယုက် ပ္ဍဲကိုပ်စၞေဟ် (frontline healthcare workers) ကေုာံ မၞိဟ်အန္တရာယ်ဇၞော် ကုကဝ်ဝိဒ်-၁၉ ပ္ဍဲဍုင်ဒိုက်ဂတ်တအ်ရ။<ref name="cepi-covax">{{cite web |title=COVAX: CEPI's response to COVID-19|url=https://cepi.net/COVAX/ |publisher=Coalition for Epidemic Preparedness Innovations (CEPI) |access-date=15 December 2020 |date=2020}}</ref><ref name="cepi-safer">{{cite web |title=New vaccines for a safer world |url=https://cepi.net/ |publisher=CEPI |access-date=15 December 2020 |date=2020}}</ref>

ဂိတုဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် နကဵုအေသဳတဳ ပ္ကောံဂွံသြန်ဒဝ်လာ ၂.၄ အမေရိကာန်ဒဝ်လာတုဲ နကဵု ကဝ်ဝက် ကေုာံ CEPI ဂွံဆဵုကေတ် လၟောဝ်ဝက်သိန် ဒစိတ် ရ။ ဂကောံဏအ်ဂှ် ဒှ်ဂကောံဇၞော်အိုတ် မဆေင်ကဵု ပ္ဍဲအရာမပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ပါလုပ်လဝ် သီုဖအိုတ် ဍုင် ၁၈၉ ရးနိဂီု။<ref name="cepi-portfolio">{{cite web |title=Our portfolio: partnerships to develop vaccines against COVID-19 |url=https://cepi.net/research_dev/our-portfolio/ |publisher=CEPI |access-date=15 December 2020 |date=2020}}</ref><ref name="who189">{{cite web|date=4 December 2020|title=Global equitable access to COVID-19 vaccines estimated to generate economic benefits of at least US$ 153 billion in 2020–21, and US$ 466 billion by 2025, in 10 major economies, according to new report by the Eurasia Group|url=https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21|access-date=11 December 2020|publisher=World Health Organization}}</ref> သၞာံ ၂၀၂၀ လပါ်စဂှ် နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် ကလိဂွံ သြန်ထံက်ပင် နူကဵု ပန်စှ်ောဍုင် သြန်ဒဝ်လာအမေရိကာန် ၈ ဗဳလဳယာန် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ရ။<ref name="waked">{{Cite web|last=Wake|first=Damon|date=2020-05-04|title=EU spearheads $8 billion virus fundraiser|url=https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|url-status=live|archive-url=https://web.archive.org/web/20200629033556/https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|archive-date=29 June 2020|access-date=2020-05-04|publisher=Yahoo Finance|name-list-style=vanc}}</ref>

ဂိတုဂျူလာင်ဂှ် ဂကောံထတ်ယုက်ဂၠးကဝ် လလောင်တြး ဍုင် ၁၆၅ ဍုင် မပစၞးကု ကောန်မၞိဟ်ဂၠးတိ ၆၀% တုပ်စိုတ် အစဳအဇန်ကဝ်ဝက်တုဲ ကဵုလဝ် ဒုင်လဝ်ဂတိ တုပ်လဝ်စိုတ် ကၞောတ်သၞာံ ၂၀၂၁ မ္ဂး ကောန်ဍုင်ညးတအ် ၂၀% ဂှ် သ္ကလိဂွံ ဝက်သိန်ရောင်။<ref name="covax">{{cite press release |title=More than 150 countries engaged in COVID-19 vaccine global access facility |url=https://www.who.int/news-room/detail/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility |publisher=World Health Organization |access-date=25 July 2020 |date=15 July 2020 |quote=COVAX is the only truly global solution to the COVID-19 pandemic. For the vast majority of countries, whether they can afford to pay for their own doses or require assistance, it means receiving a guaranteed share of doses and avoiding being pushed to the back of the queue, as we saw during the H1N1 pandemic a decade ago. Even for those countries that are able to secure their own agreements with vaccine manufacturers, this mechanism represents, through its world-leading portfolio of vaccine candidates, a means of reducing the risks associated with individual candidates failing to show efficacy or gain licensure. |archive-date=15 July 2020 |archive-url=https://web.archive.org/web/20200715152301/https://www.who.int/news-room/detail/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility |url-status=live }}</ref>

ဂကောံပံင်ကောံဂၠးကဝ် သွက်စဵုဒၞာယဲကမၠောအ် (The Global Research Collaboration for Infectious Disease Preparedness - GLoPID-R) ဂှ် ပံင်တောဲကၠောန် ကုဂကောံထတ်ယုက်ဂၠးကဝ် ကေုာံ ရးနိဂီုဂမၠိုင် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉ရ။<ref>{{Cite web |title=GloPID: Novel coronavirus COVID-19 |url=https://www.glopid-r.org/our-work/novel-coronavirus-covid-19 |website=glopid-r.org |access-date=2020-05-02 |archive-url=https://web.archive.org/web/20200502035337/https://www.glopid-r.org/our-work/novel-coronavirus-covid-19/ |archive-date=2 May 2020 |url-status=live | quote =GloPID-R Members and other major players involved in infectious disease outbreaks worldwide reacted rapidly to this emerging epidemic, working closely with the WHO to identify the specific funding research priorities needed to tackle the disease. }}</ref><ref name=can-research/>တုဲပၠန် International Severe Acute Respiratory ကေုာံ Emerging Infection Consortium တအ်ဂှ် ဒှ်ဂကောံလ္ၚတ်မကဵုပရိုင်တင်ဂၞင် ပညာ ပ္ဍဲအရာမပသုတေသန ကဝ်ဝိဒ်-၁၉ ကေုာံ ကဵုပညာကုညးဍုင်ကွာန်တအ် သီုကဵု ပ္ဍဲအရာမပရးဝက်သိန်တအ်ရ။<ref name="isaric">{{Cite web|title=ISARIC: COVID-19 clinical research resources|url=https://isaric.tghn.org/covid-19-clinical-research-resources/|date=2020-04-27|publisher=ISARIC|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200330135638/https://isaric.tghn.org/covid-19-clinical-research-resources/|archive-date=30 March 2020|url-status=live}}</ref>

ပ္ဍဲ ၄ ဂျောန်ဂှ် ပူဂိုလ် ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ကၠောန်ဗဒှ် ကောံဓရီုသကိုပ်သက သုမ္မိတ် (summit) ပ္ဍဲဍုင်လာန်ဒါန်၊ ယူကေ၊ ဂှ် မၞိဟ်နူ ၅၂ ဍုင်တိုန်စိုပ်၊ သကိုပ်သကဍုင် ၃၅ ဍုင်၊ နူကဵု ဂျဳ၇ တအ်ကီု သီုကဵု ဂျဳ၂၀ဂှ် ကလိဂွံ သြန်ဗွဝ် ၈ ဗဳလဳယာန် သွက်ဂွံထံက်ပင် မဟာမိတ်ဂၠးကဝ် သွက်ဝက်သိန် ကေုာံ အိမ်မုန် (Global Alliance for Vaccines and Immunisation - GAVI) သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ကဵုဂဥုဲဝက်သိန် ကုကောန်ၚာ် ၃၀၀ ဗဳလဳယာန် မနွံပ္ဍဲဍုင်ဒိုက်ဂတ်တအ် ပ္ဍဲအကြာသၞာံ ၂၀၁၅ ရ။<ref name="gavi-summit">{{Cite web|title=Global Vaccine Summit 2020: World leaders make historic commitments to provide equal access to vaccines for all|url=https://www.gavi.org/news/media-room/world-leaders-make-historic-commitments-provide-equal-access-vaccines-all|access-date=2020-06-04|publisher=Global Alliance for Vaccines and Immunisation|date=2020-06-04|archive-url=https://web.archive.org/web/20200606161748/https://www.gavi.org/news/media-room/world-leaders-make-historic-commitments-provide-equal-access-vaccines-all|archive-date=6 June 2020|url-status=live}}</ref>သြန်ဒါန် ဂၠိုင်အိုတ် ၁.၆ ဗဳလဳယာန် နူကဵု The Gates Foundation<ref>{{Cite press release |publisher=The Bill & Melinda Gates Foundation|via=PR Newswire|title=Bill & Melinda Gates Foundation pledges {{US$|1.6}}{{nbsp}}billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines|url=https://www.prnewswire.com/news-releases/bill--melinda-gates-foundation-pledges-1-6-billion-to-gavi-the-vaccine-alliance-to-protect-the-next-generation-with-lifesaving-vaccines-301070878.html|access-date=2020-06-04|date=2020-06-04|archive-url=https://web.archive.org/web/20200604165907/https://www.prnewswire.com/news-releases/bill--melinda-gates-foundation-pledges-1-6-billion-to-gavi-the-vaccine-alliance-to-protect-the-next-generation-with-lifesaving-vaccines-301070878.html|archive-date=4 June 2020|url-status=live}}</ref> ကေုာံ သြန်ပံင်ဗြိတိန် ၃၃၀ မဳလဳယာန် ဇၟာပ်သၞာံ ပွိုင် မသုန်သၞာံ နူကဵု အလဵုအသဳဗြိတိန် (မတုပ်သၟဟ်ကဵု ဒဝ်လာအမေရိကာန် ၂.၁ ဗဳလဳယာန် ပ္ဍဲ ဂျောန် ၂၀၂၀)။<ref name=gavi-summit/>

ပ္ဍဲဒဳဇြေမ်ဗါ ဂှ် နကဵု Gates Foundation ဆက်ကဵုဒါန် သြန်ဒဝ်လာ ၂၅၀ မဳလဳယာန်ပၠန် သွက်ဂွံကဵု ကပေါတ်စွမ်ကဝ်ဝိဒ်-၁၉၊ လွဳယဲ ကေုာံ ဝက်သိန် သွက်ဍုင်ဒိုက်ဂတ် ပ္ဍဲသၞာံ ၂၀၂၁ တုဲ သြန်ဗွဝ်သီုဖအိုတ် ဒှ်အာ သြန်ဒဝ်လာအမေရိကာန် ၁.၇၅ ဗဳလဳယာန်။<ref name="gates12-10">{{cite news |first1=Haley | last1=Yamada |first2=Jon | last2=Schlosberg |first3=Seni | last3=Tienabeso |title=Bill and Melinda Gates Foundation announces $250 million COVID vaccine commitment |url=https://abcnews.go.com/Technology/bill-melinda-gates-foundation-announces-250-million-covid/story?id=74651890 |access-date=11 December 2020 |work=ABC News - Technology |date=10 December 2020}}</ref><ref name="gates12-9">{{cite news |title=Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world |url=https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/12/Bill-and-Melinda-Gates-call-for-collaboration-innovation-to-deliver-COVID-19-breakthroughs |access-date=11 December 2020 |work=Bill & Melinda Gates Foundation |date=9 December 2020}}</ref>


====Coalition for Epidemic Preparedness Innovations====
A multinational organization formed in 2017, CEPI is working with international health authorities and vaccine developers to create vaccines for preventing epidemics.<ref name="cepi-safer" /> CEPI has organized a {{US$|2}}{{nbsp}}billion fund in a global partnership between public, private, philanthropic, and civil society organizations for accelerated research and clinical testing of nine COVID-19 vaccine candidates, with the 2020–21 goal of supporting several candidate vaccines for full development to licensing.<ref name="thanh2" /><ref name="yamey">{{Cite journal|vauthors=Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK|date=May 2020|title=Ensuring global access to COVID‑19 vaccines|journal=Lancet|volume=395|issue=10234|pages=1405–06|doi=10.1016/S0140-6736(20)30763-7|pmc=7271264|pmid=32243778|quote=CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least {{US$|2}}{{nbsp}}billion. This estimate includes Phase{{nbsp}}1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase{{nbsp}}2 and{{nbsp}}3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.|doi-access=free}}</ref><ref name="cepi-portfolio" /> The United Kingdom, Canada, Belgium, Norway, Switzerland, Germany and the Netherlands had already donated {{US$|915}}{{nbsp}}million to CEPI by early May.<ref name="waked" /><ref name="reuters">{{Cite news|date=2020-04-27|title=Special Report: Countries, companies risk billions in race for coronavirus vaccine|first1 = Julie | last1 = Steenhuysen |first2 = Peter | last2 = Eisler |first3 = Allison | last3 = Martell |first4 = Stephanie | last4 = Nebehay |work=Reuters|url=https://www.reuters.com/article/health-coronavirus-vaccine-idUSL2N2CF0JG|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200515031817/https://www.reuters.com/article/health-coronavirus-vaccine-idUSL2N2CF0JG|archive-date=15 May 2020|url-status=live | name-list-style=vanc }}</ref> The Gates Foundation, a private [[charitable organization]] dedicated to vaccine research and distribution, is donating {{US$|250}}{{nbsp}}million in support of CEPI for research and public educational support on COVID‑19 vaccines.<ref name="sanger">{{Cite news|last1=Sanger|first1=David E.|last2=Kirkpatrick|first2=David D.|last3=Zimmer|first3=Carl|last4=Thomas|first4=Katie|last5=Wee|first5=Sui-Lee|date=2020-05-02|title=With Pressure Growing, Global Race for a Vaccine Intensifies|work=[[The New York Times]]|url=https://www.nytimes.com/2020/05/02/us/politics/vaccines-coronavirus-research.html|access-date=2020-05-02|issn=0362-4331|archive-url=https://web.archive.org/web/20200511003506/https://www.nytimes.com/2020/05/02/us/politics/vaccines-coronavirus-research.html|archive-date=11 May 2020|url-status=live | name-list-style=vanc }}</ref><ref>{{Cite news|title=Bill Gates thinks there are 8 to 10 promising coronavirus vaccine candidates and one could be ready in as little as 9 months|url=https://www.businessinsider.com/bill-gates-10-promising-coronavirus-vaccine-candidates-2020-5|last=Hamilton|first=Isobel Asher|date=2020-05-01|work=Business Insider|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200516101559/https://www.businessinsider.com/bill-gates-10-promising-coronavirus-vaccine-candidates-2020-5|archive-date=16 May 2020|url-status=live | name-list-style=vanc }}</ref>

Over 2020 throughout the pandemic, CEPI was funding the development of nine vaccine candidates in a portfolio deliberately made diverse across different vaccine technologies to minimize the typically high risk of failure inherent in vaccine development.<ref name=cepi-portfolio/><ref name="cepi-jackson">{{cite web |first1=Nick | last1=Jackson |title=Why we need a "portfolio approach" to COVID-19 vaccine development |url=https://cepi.net/news_cepi/why-we-need-a-portfolio-approach-to-covid-19-vaccine-development/ |publisher=CEPI |access-date=15 December 2020 |date=28 September 2020}}</ref> As of December, the vaccine research organizations and programs being supported by CEPI were Clover Biopharmaceuticals (vaccine candidate, SCB-2019), [[CureVac]], [[Inovio]], [[Institut Pasteur]] (vaccine candidate, MV-SARS-CoV-2), [[Moderna]], [[Novavax]], [[AZD1222]] (University of Oxford-AstraZeneca), [[Hong Kong University]], and SK bioscience (vaccine candidate, GBP510).<ref name=cepi-portfolio/><ref name="cepi-covax-port">{{cite web |title=CEPI's COVID-19 vaccine portfolio |url=https://cepi.net/COVAX/ |publisher=CEPI |access-date=15 December 2020 |date=2020}}</ref><ref name="cepi-skb">{{cite web |title=CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine |url=https://cepi.net/news_cepi/cepi-and-sk-bioscience-to-develop-next-generation-covid-19-vaccine/ |publisher=CEPI |access-date=15 December 2020 |date=9 December 2020}}</ref>

==နိဿဲ==
{{reflist}}

==Footnotes==
{{notelist}}

==Further reading==
* {{cite book|last=Vogel|first=Patric U. B.|date=2020|title=COVID-19 : Suche nach einem Impfstoff|series=Essentials|url=https://link.springer.com/book/10.1007/978-3-658-31340-1|location=Wiesbaden|publisher=Springer Fachmedien Wiesbaden GmbH|doi=10.1007/978-3-658-31340-1|isbn=978-3-658-31340-1|oclc=1199717422}}
* {{cite journal |vauthors=Funk CD, Laferrière C, Ardakani A |title=A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic |journal=Front Pharmacol |volume=11 |page=937 |date=2020 |pmid=32636754 |pmc=7317023 |doi=10.3389/fphar.2020.00937 |doi-access=free}}
* {{cite web | last1=Johnson | first1=Carolyn Y. | last2=Mufson | first2=Steven | name-list-style = vanc | title=Can old vaccines from science's medicine cabinet ward off coronavirus? | website=[[The Washington Post]] | date=11 June 2020 | url=https://www.washingtonpost.com/health/2020/06/11/can-old-vaccines-sciences-medicine-cabinet-ward-off-coronavirus/ }}
* {{cite document | title=Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry | url=https://www.fda.gov/media/139638/download | format=PDF | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=June 2020 | lay-url=https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19 }}
* {{cite web | first1=Carl | last1=Zimmer | first2=Knvul | last2=Sheikh | first3=Noah | last3=Weiland | name-list-style = vanc | title=A New Entry in the Race for a Coronavirus Vaccine: Hope | website=[[The New York Times]] | date=20 May 2020 | url=https://www.nytimes.com/2020/05/20/health/coronavirus-vaccines.html }}
*{{Cite web|last=Haelle|first=Tara|date=12 December 2020|title=Every Covid-19 Vaccine Question You'll Ever Have, Answered|url=https://elemental.medium.com/every-covid-19-vaccine-question-youll-ever-have-answered-9a0eeb334ded|access-date=12 December 2020|website=Medium}}

==External links==
{{Wikiquote}}
* {{cite web | title=Coronavirus Vaccine Tracker | website=[[The New York Times]] | url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html }}
* [https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker COVID-19 vaccine tracker, Regulatory Focus]
* {{cite web | title=STAT's Covid-19 Drugs and Vaccines Tracker | work=[[Stat (website)|Stat]] | url=https://www.statnews.com/feature/coronavirus/drugs-vaccines-tracker/#vaccines }}
* {{cite press release | title=Biopharma Leaders Unite to Stand with Science | via=[[Business Wire]] | date=8 September 2020 | url=https://www.businesswire.com/news/home/20200908005282/en/ }}
* {{cite web | url=https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf | title=Protocol mRNA-1273-P301 | publisher=[[Moderna]] }}
* {{cite web | url=https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf | title=Protocol C4591001 PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) | publisher=[[Pfizer]] }}
* {{cite web | url=https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf | title=Protocol AZD1222 – D8110C00001 | publisher=[[AstraZeneca]] }}
* {{cite web | url=https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol | format=PDF | title=Protocol VAC31518COV3001; Phase 3 | publisher=[[Janssen Pharmaceutica|Janssen Vaccines & Prevention]] }}
* {{cite web | last=Levine | first=Hallie | title=The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works | publisher=Johnson & Johnson | date=23 September 2020 | url=https://www.jnj.com/innovation/the-5-stages-of-covid-19-vaccine-development-what-you-need-to-know-about-how-a-clinical-trial-works }}
* {{cite web | title=COVID-19 vaccines: development, evaluation, approval and monitoring | publisher=[[European Medicines Agency]] | url=https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring }}
* {{cite web | title=Vaccine Development – 101 | publisher=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/vaccine-development-101 }}


[[Category:ပရေင်ထတ်ယုက်]]
[[Category:BEHM]]
